Evidence map›Paper›PMID 40410387›Full record

ArticleEuropean journal of human genetics : EJHG2025

Biallelic loss-of-function variants in ZNF142 are associated with a robust DNA methylation signature affecting a limited number of genomic loci.

Mathis Hildonen, Andrea Ciolfi, Marco Ferilli, Camilla Cappelletti, Chadi Al Alam, David J Amor, Tahsin Stefan Barakat, Valérie Benoit, Ohad Shmuel Birk, Bert Callewaert and 31 more

Abstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

41 authors.

Mathis Hildonen *Department of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark.ORCID 0000-0002-2016-3670
Andrea Ciolfi *Molecular Genetics and Functional Genomics, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.ORCID 0000-0002-6191-0978
Marco Ferilli *Molecular Genetics and Functional Genomics, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Camilla CappellettiMolecular Genetics and Functional Genomics, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy.
Chadi Al AlamDepartment of Pediatric Neurology, American center for Psychiatry and Neurology, Abu Dhabi, UAE.
David J AmorDepartment of Paediatrics, University of Melbourne, Murdoch Children's Research Institute, Melbourne, Australia.ORCID 0000-0001-7191-8511
Tahsin Stefan BarakatDeparment of Clinical Genetics, Erasmus MC, 3000CA, Rotterdam, The Netherlands.ORCID 0000-0003-1231-1562
Valérie BenoitIPG, Centre for Human Genetics, Charleroi, Belgium.ORCID 0000-0002-1098-9452
Ohad Shmuel BirkGenetics Institute, Soroka University Medical Center, Beer-Sheva, Israel.ORCID 0000-0003-1430-1296
Bert CallewaertCenter for Medical Genetics, Ghent University Hospital, 9000, Ghent, Belgium.ORCID 0000-0002-9743-4205
Ana Cazurro-GutiérrezPaediatric Neurology Research Group, Vall d'Hebron Institut de Recerca, 08035, Barcelona, Spain.
Matthias De WachterDepartment of Child Neurology, Antwerp University Hospital, University of Antwerp, Edegem, Belgium.ORCID 0000-0002-6422-210X
Martine Doco-FenzySFR CAP SANTE, Service de génétique CHU Reims, 51092, Reims, France.
Paulino Gómez-PuertasMolecular Modeling Group, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), E-28049, Madrid, Spain.ORCID 0000-0003-3131-729X
Trine Bjørg HammerDepartment of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark.
Rami Abou JamraInstitute of Human Genetics, University of Leipzig Medical Center Leipzig, 04103, Leipzig, Germany.ORCID 0000-0002-1542-1399
Rauan KaiyrzhanovDepartment of Neuromuscular Disorders, University College London Institute of Neurology, WC1N 3BG, London, UK.
Shinichi KameyamaDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, 236-0004, Yokohama, Japan.
Boris KerenDepartment of Medical Genetics, Pitié-Salpêtrière Hospital, AP-HP.Sorbonne Université, 75013, Paris, France.
Christina KresgeRutgers New Jersey Medical School, Newark, NJ, USA.
Ilona KreyInstitute of Human Genetics, University of Leipzig Medical Center Leipzig, 04103, Leipzig, Germany.ORCID 0000-0002-9168-7615
Damien LedererIPG, Centre for Human Genetics, Charleroi, Belgium.
Iñigo Marcos-AlcaldeMolecular Modeling Group, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), E-28049, Madrid, Spain.
Reza MaroofianDepartment of Neuromuscular Disorders, University College London Institute of Neurology, WC1N 3BG, London, UK.ORCID 0000-0001-6763-1542
Naomichi MatsumotoDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, 236-0004, Yokohama, Japan.ORCID 0000-0001-9846-6500
Takeshi MizuguchiDepartment of Human Genetics, Yokohama City University Graduate School of Medicine, 236-0004, Yokohama, Japan.
Lip-Hen MoeyDepartment of Clinical Genetics, Penang Hospital, 10450, Georgetown, Malaysia.
Angela MorganSpeech and Language, Murdoch Children's Research Institute, 3052, Melbourne, Australia.ORCID 0000-0003-1147-7405
Francina MunellPaediatric Neurology Research Group, Vall d'Hebron Institut de Recerca, 08035, Barcelona, Spain.
Konrad PlatzerInstitute of Human Genetics, University of Leipzig Medical Center Leipzig, 04103, Leipzig, Germany.ORCID 0000-0001-6127-6308
Beth A PletcherRutgers New Jersey Medical School, Newark, NJ, USA.
David Ros-PardoMolecular Modeling Group, Centro de Biología Molecular Severo Ochoa, CBMSO (CSIC-UAM), E-28049, Madrid, Spain.
Lynne RumpingDepartment of Medical Genetics, Antwerp University Hospital, University of Antwerp, 2650, Edegem, Belgium.
Katalin SzakszonUniversity of Debrecen, Faculty of Medicine, Clinical Center, Institute of Paediatrics, 4032, Debrecen, Hungary.
Kristof Van SchilDepartment of Medical Genetics, Antwerp University Hospital, University of Antwerp, 2650, Edegem, Belgium.ORCID 0000-0001-5299-8851
Edgard VerduraPaediatric Neurology Research Group, Vall d'Hebron Institut de Recerca, 08035, Barcelona, Spain.
Julie VogtWest Midlands Regional Genetics Service, Birmingham Women's and Children's Hospital, B15 2TG, Birmingham, UK.
Evangeline WassmerNeurology, Birmingham Women's and Children's Hospital, B4 6 NH, Birmingham, UK.
Mina ZamaniCenter for Genomics and Systems Biology, Department of Biology, New York University, New York, NY, 10003, USA.
Zeynep TümerDepartment of Clinical Genetics, Copenhagen University Hospital, Rigshospitalet, 2100, Copenhagen, Denmark. Zeynep.tumer@regionh.dk.ORCID 0000-0002-4777-5802
Marco TartagliaMolecular Genetics and Functional Genomics, Bambino Gesù Children's Hospital, IRCCS, 00146, Rome, Italy. marco.tartaglia@opbg.net.ORCID 0000-0001-7736-9672

Funding

Ministero della Salute (Ministry of Health, Italy) 5x1000_2023Ministero della Salute (Ministry of Health, Italy) Current Research FundsMinistero della Salute (Ministry of Health, Italy) PNRR-MR1-2022-12376811Ministero della Salute (Ministry of Health, Italy) Ricerca Corrente 2024
6 · The paper itself

Abstract

Biallelic inactivating variants in ZNF142 underlie a clinically variable neurodevelopmental disorder. ZNF142 is a zinc-finger transcription factor with potential roles on chromatin organization, implying a possible association of ZNF142 loss of function with perturbed genome-wide DNA methylation (DNAm) pattern. We performed EPIC array-based methylation profiling of peripheral blood-derived DNA samples from 27 individuals with biallelic ZNF142 inactivating variants, together with 6 heterozygous carriers and 40 controls. A DNAm signature discovery pipeline was applied by using 440 controls for discovery and validation analyses, and a machine-learning model was trained to classify 8 individuals carrying ZNF142 variants of uncertain clinical significance. Analyses directed to explore the genome-wide DNAm landscape in affected individuals revealed 88 differentially methylated probes constituting the minimal informative set specific to ZNF142 loss of function. This reproducible pattern of DNAm changes involved regulatory regions of a small number of genes. The DNAm signature derived from peripheral blood allowed us to diagnose individuals carrying biallelic inactivating ZNF142 variants when applied to fibroblasts. Our findings provide evidence that biallelic loss-of-function ZNF142 variants result in a specific and robust DNAm signature. The identified DNAm pattern suggests occurrence of a methylation disturbance involving a small number of loci that appears to be shared by different cell lineages.

Indexed as

DNA MethylationLoss of Function MutationRepressor ProteinsAllelesFemaleHumansMaleRepressor Proteins

Identifiers

PMID40410387
PMCPMC12229324

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.